Trust Bio-sonics, Inc. is a Taiwan based pharmaceutic company and a worldwide leader in microsphere technologies for contrast-enhanced ultrasound imaging and ultrasound drug delivery. The Company mainly targets the disease areas of cardiovascular diseases and cancers aiming to provide patients with the most advanced early diagnosis and treatment solutions. Trust Bio-sonics is now developing two clinical products for general imaging and the diagnosis of Acute Coronary Syndrome (ACS). The leading candidate, TBS-002 (505b1 New Drug), has finished the enrollment of its Phase 1/2 trial in 2020 (USFDA, TFDA).
- 2021 National Innovation Award
- 2020 Beyond BioMed Accelerator
- 2020 SmartLabs Global Launch Pogram
- 2019 National Innovation Award
- 2015 CDE IDX case
- 2014 SVT Immersion Program